What question did this study set out to answer?

To assess whether flecainide therapy can provoke adverse cardiac events or unmask Brugada syndrome features in patients with long QT-3 syndrome.

Is Flecainide Dangerous in Long QT‐3 Patients?

View Full Paper

Ask AI

Bookmark

Why the study?

Does oral flecainide induce adverse events in patients with long QT-3 syndrome?

To assess whether flecainide therapy can provoke adverse cardiac events or unmask Brugada syndrome features in patients with long QT-3 syndrome.
Clinical case evaluation of an individual with established long QT-3 syndrome receiving oral flecainide therapy.
Diagnostic review of electrocardiogram changes and symptomatic adverse outcomes following drug administration.
Oral flecainide provoked a clinical episode of syncope in the patient with long QT-3 syndrome.
The medication unmasked a diagnostic Brugada electrocardiogram pattern, demonstrating potential proarrhythmic risks linked to shared SCN5A gene mutations.

Does oral flecainide induce adverse events in patients with long QT-3 syndrome?

Population

1 patient with known long QT-3 syndrome

Intervention

Oral flecainide

Outcome

Syncope with a Brugada ECG patternsafety

Flecainide, although used to shorten QT interval in long QT-3 syndrome, may induce syncope and a Brugada ECG pattern in these patients.

No takes yet. Share an insight, caveat, or question.

Flecainide use in LQT3 warrants caution; this case leaves open its safety profile and requires prospective validation.

Beinart et al. (2008) studied this question.

View Full Paper

Ask AI

Bookmark